HonCode

Go Back   HER2 Support Group Forums > General Cancer News
Reload this Page T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer pati
Register Gallery FAQ Members List Calendar Today's Posts

General Cancer News Latest Breast Cancer News from Moreover Technologies

Reply
 
Thread Tools Display Modes
Old 12-08-2022, 01:17 AM   #1
News
Senior Member
 
News's Avatar
 
Join Date: Oct 2007
Posts: 18,959
T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer pati
Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

More...
News is offline   Reply With Quote
Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -7. The time now is 11:07 AM.
Contact Us - HER2 Support Group - Archive - Privacy Statement - Top

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter